|
RU2086544C1
(ru)
|
1991-06-13 |
1997-08-10 |
Хоффманн-Ля Рош АГ |
Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
|
|
US5820915A
(en)
|
1996-06-27 |
1998-10-13 |
Bioavailability Systems, L.L.C. |
Method for the preparation of a first-pass effective citrus-derived substance and product thereof
|
|
US6124477A
(en)
|
1996-06-27 |
2000-09-26 |
Bioavailability Systems, Llc |
Anti-first-pass effect compounds
|
|
US5990154A
(en)
|
1997-05-30 |
1999-11-23 |
Bioavailability Systems, L.L.C. |
Anti-first-pass effect compounds and citrus extract
|
|
US6063809A
(en)
|
1997-08-26 |
2000-05-16 |
Bioavailability Systems, Llc |
Anti-first-pass effect compounds
|
|
US6248776B1
(en)
|
1997-08-26 |
2001-06-19 |
Bioavailability Systems, L.L.C. |
Anti-first-pass effect compounds
|
|
US20040058982A1
(en)
|
1999-02-17 |
2004-03-25 |
Bioavailability System, Llc |
Pharmaceutical compositions
|
|
US5993887A
(en)
|
1998-06-29 |
1999-11-30 |
Bioavailability Systems, L.L.C. |
Safe citrus juice and process for preparation
|
|
WO2004037827A1
(en)
|
2000-10-20 |
2004-05-06 |
Bioavailability Systems, Llc |
Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates
|
|
US7968569B2
(en)
|
2002-05-17 |
2011-06-28 |
Celgene Corporation |
Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione
|
|
WO2005087728A1
(en)
|
2004-03-11 |
2005-09-22 |
Sequoia Pharmaceuticals, Inc. |
Resistance-repellent retroviral protease inhibitors
|
|
AU2005244121B2
(en)
|
2004-05-07 |
2012-01-19 |
Sequoia Pharmaceuticals, Inc. |
Resistance-repellent retroviral protease inhibitors
|
|
US20090281114A1
(en)
|
2008-05-08 |
2009-11-12 |
Fabre-Kramer Pharmaceuticals, Inc. |
Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction
|
|
CL2009001152A1
(es)
|
2008-05-13 |
2009-10-16 |
Array Biopharma Inc |
Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa.
|
|
US9073947B2
(en)
|
2011-06-10 |
2015-07-07 |
Merck Patent Gmbh |
Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity
|
|
US8466159B2
(en)
*
|
2011-10-21 |
2013-06-18 |
Abbvie Inc. |
Methods for treating HCV
|
|
TWI599356B
(zh)
|
2012-09-26 |
2017-09-21 |
安羅格製藥有限責任公司 |
抑制突變型ｃ－ｋｉｔ的方法
|
|
ES2750523T3
(es)
|
2012-12-18 |
2020-03-26 |
Almirall Sa |
Derivados de ciclohexil y quinuclidinil carbamato que tienen actividades de agonista beta2 adrenérgicos y antagonistas muscarínicos M3
|
|
US9458124B2
(en)
|
2013-02-06 |
2016-10-04 |
Wayne State University |
Substituted pyran derivatives
|
|
AU2014249233A1
(en)
|
2013-03-13 |
2015-09-24 |
The Regents Of The University Of Michigan |
Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
|
|
US11596636B2
(en)
|
2014-01-14 |
2023-03-07 |
The Trustees Of The University Of Pennsylvania |
Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors
|
|
US20170119769A1
(en)
|
2014-06-10 |
2017-05-04 |
The Trustees Of The University Of Pennsylvania |
Scaffolds for inhibitors of menin-mll interactions
|
|
US20170232030A1
(en)
*
|
2014-08-13 |
2017-08-17 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
CN105732636B
(zh)
|
2014-12-30 |
2020-04-21 |
广东东阳光药业有限公司 |
杂芳化合物及其在药物中的应用
|
|
WO2016197027A1
(en)
|
2015-06-04 |
2016-12-08 |
Kura Oncology, Inc. |
Methods and compositions for inhibiting the interaction of menin with mll proteins
|
|
BR112018012707A2
(pt)
|
2015-12-22 |
2019-01-29 |
Vitae Pharmaceuticals Inc |
inibidores da interação de menin-mll
|
|
AU2017212572A1
(en)
|
2016-01-26 |
2018-08-23 |
Memorial Sloan-Kettering Cancer Center |
Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia
|
|
US10752639B2
(en)
|
2016-03-16 |
2020-08-25 |
Kura Oncology, Inc. |
Bridged bicyclic inhibitors of menin-MLL and methods of use
|
|
CN109415337B
(zh)
|
2016-05-02 |
2022-01-18 |
密执安大学评议会 |
作为多发性内分泌腺瘤蛋白抑制剂的哌啶
|
|
CN109562113A
(zh)
|
2016-05-10 |
2019-04-02 |
C4医药公司 |
用于靶蛋白降解的螺环降解决定子体
|
|
ES2831084T3
(es)
*
|
2016-06-10 |
2021-06-07 |
Vitae Pharmaceuticals Inc |
Inhibidores de la interacción menina-MLL
|
|
CN118359610A
(zh)
|
2016-09-16 |
2024-07-19 |
生命医药有限责任公司 |
Menin-mll相互作用的抑制剂
|
|
CN110691779B
(zh)
|
2017-03-24 |
2023-10-10 |
库拉肿瘤学公司 |
治疗血液系统恶性肿瘤和尤因肉瘤的方法
|
|
JP7307729B2
(ja)
|
2017-12-20 |
2023-07-12 |
ヤンセン ファーマシューティカ エヌ．ベー． |
メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
|
|
EP3740491A1
(en)
*
|
2018-01-18 |
2020-11-25 |
Array Biopharma, Inc. |
Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
|
|
KR20200136958A
(ko)
|
2018-03-30 |
2020-12-08 |
더 리젠츠 오브 더 유니버시티 오브 미시간 |
공유 메닌 억제제로서의 피페리딘 화합물
|
|
AU2019337547A1
(en)
|
2018-09-13 |
2021-03-18 |
Merck Sharp & Dohme Llc |
Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer
|
|
JP2022503792A
(ja)
|
2018-09-26 |
2022-01-12 |
クラ オンコロジー，インク． |
メニン阻害剤を用いた血液悪性腫瘍の処置
|
|
WO2020142557A1
(en)
|
2018-12-31 |
2020-07-09 |
Biomea Fusion, Llc |
Irreversible inhibitors of menin-mll interaction
|
|
IL297039A
(en)
|
2020-04-07 |
2022-12-01 |
Syndax Pharmaceuticals Inc |
Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
|
|
JP2024520900A
(ja)
|
2021-05-12 |
2024-05-27 |
シンダックス ファーマシューティカルズ， インコーポレイテッド |
癌の治療のための組合せ
|
|
AR125866A1
(es)
|
2021-05-14 |
2023-08-23 |
Syndax Pharmaceuticals Inc |
Inhibidores de la interacción de menina-mll
|
|
JP7891524B2
(ja)
|
2021-08-11 |
2026-07-16 |
バイオメア フュージョン，インコーポレイテッド |
真性糖尿病に対するメニン－ｍｌｌ相互作用の共有結合性阻害剤
|
|
MX2024007201A
(es)
|
2021-12-15 |
2024-08-06 |
Dana Farber Cancer Inst Inc |
Direccionamiento terapeutico del tumor del estroma gastrointestinal (gist) mediante la alteracion del complejo epigenetico de menina-mll.
|
|
IL326799A
(en)
|
2023-08-28 |
2026-04-01 |
Syndax Pharmaceuticals Inc |
Aryl ether analogs as inhibitors of the menin-mll interaction
|